UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS

The following unaudited pro forma combined financial statements are provided for informational purposes only and do not purport to represent what the actual combined results of operations or the combined financial position of the combined company would be had the Acquisition Transaction occurred on the dates assumed, nor are they necessarily indicative of future combined results of operations or combined financial position. The unaudited combined financial statements do not reflect any cost savings or synergies that the management of Biotricity Inc. (formerly known as Metasolutions Inc.) and iMedical Innovations Inc. could have achieved if they were together through this period.

The unaudited pro forma combined statements of operations for the periods presented give effect to the Acquisition Transaction as if they had been consummated, beginning of the earliest period presented. The unaudited pro forma balance sheets give effect to the Acquisition Transaction as if they had occurred on the dates of those balances sheets.

The effects of the Acquisition Transaction have been prepared using the purchase method of accounting and applying the assumptions and adjustments described in the accompanying notes.

We describe the assumptions underlying the pro forma adjustments in the accompanying notes, which should also be read in conjunction with these unaudited pro forma financial statements. Please read this information in conjunction with:

The audited pro forma combined financial statements should be read in conjunction with the information contained in the Current Report on Form 8-K.

1

Biotricity Inc. (formerly known as Metasolutions Inc.)

Pro Forma Combined Statements of Financial Position

As at November 30, 2015 and September 30, 2015

Expressed in US $

(Unaudited)

2

Biotricity Inc. (formerly known as Metasolutions Inc.)

Pro Forma Combined Statements of Financial Position

As at November 30, 2014 and December 31, 2014

Expressed in US $

(Unaudited)

3

Biotricity Inc. (formerly known as Metasolutions Inc.)

Pro Forma Statements of Operations and Comprehensive Loss

Expressed in US $

For the Nine months ended November 30, 2015 and September 30, 2015

(Unaudited)

4

Biotricity Inc. (formerly known as Metasolutions Inc.)

Pro Forma Statements of Operations and Comprehensive Loss

Expressed in US $

For the Twelve months ended November 30, 2014 and December 31, 2015

(Unaudited)

5

Biotricity Inc. (formerly known as Metasolutions Inc.)

Notes to Pro Forma Combined Financial Statements

(Expressed in US $)

(Unaudited)

1.

The Transaction

On February 2, 2016, Biotricity Inc., a corporation incorporated under the laws of the State of Nevada (the “Parent” and “Biotricity”), 1061806 BC LTD., a wholly owned subsidiary of Biotricity, and a corporation incorporated under the laws of the Province of British Columbia  (“Callco”), 1062024 BC LTD., a subsidiary of Callco and a corporation incorporated under the laws of the Province of British Columbia (“Exchangeco”), iMedical Innovations Inc., a corporation incorporated under the laws of the Province of Ontario (“iMedical”) and the Shareholders of  iMedical entered into an Exchange Agreement in connection with the closing of the Acquisition Transaction as detailed below:

·

Biotricity’s sole existing director resigned and a new director who is the sole director of iMedical was appointed to fill the vacancy;

·

Biotricity’s sole Chief Executive Officer and sole officer, who beneficially owned 6,500,000 shares of outstanding common stock, resigned from all positions and transferred all of his shares back for cancellation;

·

The existing management of iMedical were appointed as executive officers; and

·

The existing shareholders of iMedical entered into a transaction whereby their existing common shares of iMedical were exchanged for either (a) a new class of shares that are exchangeable for shares of Biotricity’s common stock, or (b) shares of Biotricity’s common stock, which (assuming exchange of all such exchangeable shares) would equal in the aggregate a number of shares of Biotricity’s common stock that constitute 90% of Biotricity’s issued and outstanding shares.

As a result, Biotricity’s management have determined to treat the acquisition as a reverse merger and recapitalization for accounting purposes, with iMedical as the acquirer for accounting purposes.    

2    Basis of Presentation

The unaudited pro forma combined financial information for Biotricity as at and for the nine month period ended November 30, 2015 and September 30, 2015 and twelve months period ended November 30, 2014 and December 31, 2014, respectively, has been prepared by management to reflect the Acquisition Transaction as described in Note 1.

The unaudited pro forma combined financial information that follows for the twelve months ended December 31, 2014 and November 30, 2014 have been derived from the historical audited financial statements of iMedical for the year ended December 31, 2014 and from the Quarterly Reports on Form 10-Q of Biotricity as at and for the period ended November 30, 2014.

The unaudited pro forma combined financial information that follows for the twelve months ended December 31, 2014 and November 30, 2014 have been derived from the historical audited financial statements of iMedical for the year ended December 31, 2014 and from the Quarterly Reports on Form 10-Q of Biotricity as at and for the period ended November 30, 2014.

Certain adjustments have been made while combining the two companies which are detailed in note 3. The pro forma adjustments are based on available information and assumptions that Biotricity believes are reasonable. Such adjustments are estimates and are subject to change.

6

Biotricity Inc. (formerly known as Metasolutions Inc.)

Notes to Pro Forma Combined Financial Statements

(Expressed in US $)

(Unaudited)

The Acquisition Transaction will be accounted for as a reverse acquisition in accordance with the Financial Accounting Standards Board (ASC 805, Business Combinations). Biotricity’s management has evaluated the guidance contained in ASC 805 with respect to the identification of the acquirer in the Acquisition Transaction and concluded, based on a consideration of the pertinent facts and circumstances, that iMedical will acquire Biotricity for financial accounting purposes. Accordingly, the Acquisition Transaction has been accounted for in the unaudited pro forma combined financial statements as a continuation of the financial statements of iMedical together with an exchange of shares, to the former shareholders of Biotricity and a re-capitalization of the equity of Biotricity.

3     Pro Forma Adjustments

The unaudited pro forma combined financial statements give effect to the following adjustments:

7